SETD7 and prostate carcinoma: In addition, SET7 is reported to be a key regulator in the pathogenies of several diseases in cluding alopecia areata [69], breast cancer [37,70], tumour and cancer progression [71,72,73,74,75,76], atherosclerosis in human carotid plaques [77], chronic renal diseases, diabetes [45,78,79,80,81,82,83,84], obesity [85], ovarian cancer [86], prostate cancer [87], hepatocellular carcinoma [71], and pulmonary fibrosis [57].